This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Revance Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.762. Revance Therapeutics's 10-Year median PS Ratio is 507.462. Therefore, the Median PS Value for today is $1,401.61.
As of today (2024-04-24), Revance Therapeutics's share price is $3.67. Revance Therapeutics's Median PS Value is $1,401.61. Therefore, Revance Therapeutics's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Revance Therapeutics's Median PS Value or its related term are showing as below:
During the past 13 years, the highest Price to Median PS Value of Revance Therapeutics was 0.01. The lowest was 0.01. And the median was 0.01.
RVNC's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.665 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Revance Therapeutics Median PS Value Historical Data
The historical data trend for Revance Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Revance Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revance Therapeutics Price-to-Median-PS-Value Distribution
For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Revance Therapeutics's Price-to-Median-PS-Value falls into.
Revance Therapeutics Median PS Value Calculation
Revance Therapeutics's Median PS Value for today is calculated as
10-Year Median PS Ratio is 507.462.
Revance Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.762.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revance Therapeutics (NAS:RVNC) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Revance Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
3.67
/
1,401.61
=
0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revance Therapeutics Median PS Value Related Terms
Thank you for viewing the detailed overview of Revance Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Revance Therapeutics (Revance Therapeutics) Business Description
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RVNC has been successfully added to your 